A woman with metastatic pancreatic neuroendocrine tumor.

an for benign cysts, an upper gastroesophageal endoscopy, and a hepatobiliary iminodiacetic acid (HIDA) scan. for magnetic resonance imaging (MRI) of the multiple cystic combination of pancreatic pancreatic malignancy differential for a pancreatic mass with liver lesions in pancreatic adenocarcinoma, neuroendocrine tumors (NETs), and, more acinar cancer and solid pseudopapillary malignancy of the pancreas. Well-defined,

[1]  C. Schade-Brittinger,et al.  Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival , 2016, Neuroendocrinology.

[2]  Laura H. Tang,et al.  Objective Quantification of the Ki67 Proliferative Index in Neuroendocrine Tumors of the Gastroenteropancreatic System: A Comparison of Digital Image Analysis With Manual Methods , 2012, The American journal of surgical pathology.

[3]  J. Cameron,et al.  Pancreatic imaging mimics: part 2, pancreatic neuroendocrine tumors and their mimics. , 2012, AJR. American journal of roentgenology.

[4]  J. Mongan,et al.  Pancreatic imaging mimics: part 1, imaging mimics of pancreatic adenocarcinoma. , 2012, AJR. American journal of roentgenology.

[5]  R. Jensen,et al.  Molecular pathology and genetics of pancreatic endocrine tumours. , 2012, Journal of molecular endocrinology.

[6]  R. Pazdur,et al.  FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors. , 2012, The Oncologist.

[7]  D. Reidy-Lagunes,et al.  Systemic therapy for advanced pancreatic neuroendocrine tumors: an update. , 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

[8]  M. Lowery,et al.  Acinar cell carcinoma of the pancreas: new genetic and treatment insights into a rare malignancy. , 2011, The oncologist.

[9]  A. Scarpa,et al.  Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Laura H. Tang,et al.  Effect of Tumor Heterogeneity on the Assessment of Ki67 Labeling Index in Well-differentiated Neuroendocrine Tumors Metastatic to the Liver: Implications for Prognostic Stratification , 2011, The American journal of surgical pathology.

[11]  Y. Bang,et al.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.

[12]  D. Coppola,et al.  First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas , 2011, Cancer.

[13]  Domenico Coppola,et al.  The Pathologic Classification of Neuroendocrine Tumors: A Review of Nomenclature, Grading, and Staging Systems , 2010, Pancreas.

[14]  E. Araki,et al.  A case of ectopic adrenocorticotropic hormone-producing pancreatic neuroendocrine tumor with multiple liver metastases. , 2010, Endocrine journal.

[15]  E. Van Cutsem,et al.  90Y-edotreotide for metastatic carcinoid refractory to octreotide. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Qi Xu,et al.  Solid pseudopapillary tumor of the pancreas: a review of 553 cases in Chinese literature. , 2010, World journal of gastroenterology.

[17]  G. Abou-Alfa,et al.  Pancreatic islet cell carcinoma presenting with concurrent Cushing's and Zollinger-Ellison syndromes: case series and literature review. , 2010, European journal of gastroenterology & hepatology.

[18]  A. Kjaer,et al.  F-Fluorodeoxyglucose Positron Emission Tomography Predicts Survival of Patients with Neuroendocrine Tumors , 2010 .

[19]  R. Chetty.  An overview of practical issues in the diagnosis of gastroenteropancreatic neuroendocrine pathology. , 2009, Archives of pathology & laboratory medicine.

[20]  S. Nag,et al.  Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors. , 2009, International journal of radiation oncology, biology, physics.

[21]  C. Nutting,et al.  Minimally Invasive Techniques in Management of Hepatic Neuroendocrine Metastatic Disease , 2009, American journal of clinical oncology.

[22]  S. Willich,et al.  Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. , 2008, Endocrine-related cancer.

[23]  G. Nikou,et al.  Chromogranin A Levels in Diagnosis, Treatment and Follow-Up of 42 Patients with Non-Functioning Pancreatic Endocrine Tumours , 2008, Pancreatology (Print).

[24]  D. Morris,et al.  Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases , 2008, Cancer.

[25]  H. Pitt,et al.  Hepatic Neuroendocrine Metastases: Chemo- or Bland Embolization? , 2008, Journal of Gastrointestinal Surgery.

[26]  K. Klose,et al.  Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[27]  Manal M. Hassan,et al.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  E. Krenning,et al.  Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  R. Thakker,et al.  Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene , 2008, Human mutation.

[30]  R. Bale,et al.  68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT , 2007, Journal of Nuclear Medicine.

[31]  K. Ahrar,et al.  Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors , 2005, Cancer.

[32]  F. Minuto,et al.  Effect of short-term treatment with low dosages of the proton-pump inhibitor omeprazole on serum chromogranin A levels in man. , 2004, European journal of endocrinology.

[33]  V. Canzonieri,et al.  Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  J. Caridi,et al.  Hepatic artery embolization for control of symptoms, octreotide requirements, and tumor progression in metastatic carcinoid tumors , 2002, Journal of Gastrointestinal Surgery.

[35]  N. Reed,et al.  Management of neuroendocrine tumours. , 1999, Clinical oncology (Royal College of Radiologists (Great Britain)).

[36]  B. Skogseid,et al.  Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors , 1998, Cancer.

[37]  J. K. Martin,et al.  The Management of Patients with Advanced Carcinoid Tumors and Islet Cell Carcinomas , 1994, Annals of Internal Medicine.

[38]  S. Lipsitz,et al.  Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. , 1992, The New England journal of medicine.

[39]  D. O'Connor,et al.  Chromogranin A in uremia: progressive retention of immunoreactive fragments. , 1990, Kidney international.

[40]  J. Ajani,et al.  Islet cell tumors metastatic to the liver: effective palliation by sequential hepatic artery embolization. , 1988, Annals of internal medicine.

[41]  J. Stockman,et al.  Everolimus for Advanced Pancreatic Neuroendocrine Tumors , 2012 .

[42]  F. Bosman,et al.  WHO Classification of Tumours of the Digestive System , 2010 .

[43]  C. Schade-Brittinger,et al.  Placebo-Controlled , Double-Blind , Prospective , Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors : A Report From the PROMID Study Group , 2009 .